159989-65-8 | 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-, methanesulfonate (1:1)

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$23.00	$17.00
5mg	98%	in stock	$51.00	$36.00
10mg	98%	in stock	$89.00	$63.00
25mg	98%(HPLC)	in stock	$168.00	$118.00
50mg	98%(HPLC)	in stock	$272.00	$191.00
100mg	>97.0%(HPLC)	in stock	$445.00	$312.00
1000mg	98% by HPLC	in stock	$4,358.00	$3,051.00

Description

• Catalog Number: AA82169
• Chemical Name: 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-, methanesulfonate (1:1)
• CAS Number: 159989-65-8
• Molecular Formula: C33H49N3O7S2
• Molecular Weight: 663.8881
• MDL Number: MFCD00931436
• SMILES: CS(=O)(=O)O.O[C@@H]([C@@H](NC(=O)c1cccc(c1C)O)CSc1ccccc1)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
• NSC Number: 722664

Computed Properties

• Complexity: 922
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 5
• Heavy Atom Count: 45
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 5
• Rotatable Bond Count: 10

Literature

• Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors.

  Cancer letters 20121201

• Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission.

  The Pediatric infectious disease journal 20121101

• Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.

  Journal of the National Cancer Institute 20121017

• Inhibin beta E is upregulated by drug-induced endoplasmic reticulum stress as a transcriptional target gene of ATF4.

  Toxicology and applied pharmacology 20121015

• The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation.

  Journal of leukocyte biology 20121001

• The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.

  Haematologica 20120701

• Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer.

  The FEBS journal 20120701

• Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.

  Cell death & disease 20120701

• Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.

  The New England journal of medicine 20120621

• The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120601

• Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells.

  Journal of chemotherapy (Florence, Italy) 20120601

• Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120501

• Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.

  Pharmaceutical research 20120401

• The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.

  The Journal of antimicrobial chemotherapy 20120401

• A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120401

• Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.

  Archives of medical research 20120401

• Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion.

  Drug metabolism and disposition: the biological fate of chemicals 20120301

• Transplacental passage of nevirapine, nelfinavir and lopinavir.

  The Netherlands journal of medicine 20120301

• Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.

  Journal of medical virology 20120201

• The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.

  Molecules (Basel, Switzerland) 20120112

• The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes.

  Journal of neurochemistry 20120101

• Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101

• Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum.

  HIV clinical trials 20120101

• Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384.

  Journal of acquired immune deficiency syndromes (1999) 20111201

• Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.

  Drug metabolism and disposition: the biological fate of chemicals 20111201

• Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.

  Journal of acquired immune deficiency syndromes (1999) 20111101

• In vitro activity of antiretroviral drugs against Plasmodium falciparum.

  Antimicrobial agents and chemotherapy 20111101

• Elucidating the energetics of entropically driven protein-ligand association: calculations of absolute binding free energy and entropy.

  The journal of physical chemistry. B 20111020

• Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20111001

• Nelfinavir induces radiation sensitization in pituitary adenoma cells.

  Cancer biology & therapy 20111001

• Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.

  The Pediatric infectious disease journal 20110901

• Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.

  Current cancer drug targets 20110901

• Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

  The Journal of biological chemistry 20110819

• Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.

  British journal of cancer 20110809

• Genetic diversity of HIV type 1 in Montenegro.

  AIDS research and human retroviruses 20110801

• LC, LC-MS/TOF and MS(n) studies for the identification and characterization of degradation products of nelfinavir mesylate.

  Journal of pharmaceutical and biomedical analysis 20110601

• The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro.

  Antimicrobial agents and chemotherapy 20110601

• Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.

  Drug metabolism and disposition: the biological fate of chemicals 20110601

• Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution.

  AAPS PharmSciTech 20110601

• HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20110501

• [Effects of daily administration of a stavudine/nelfinavir association on the fetuses and placentas of female albino rats].

  Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 20110501

• Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110401

• Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.

  PLoS computational biology 20110401

• Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus.

  Pharmacotherapy 20110301

• Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.

  Journal of lipid research 20110201

• Radiosensitivity of human papillomavirus-related tumors: in regard to Gupta et al. (Int J Radiat Oncol Biol Phys 2009;74:928-933).

  International journal of radiation oncology, biology, physics 20110201

• Analysis of nelfinavir-induced endoplasmic reticulum stress.

  Methods in enzymology 20110101

• Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp.

  Experimental parasitology 20101201

• Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Effect of ethanol on spectral binding, inhibition, and activity of CYP3A4 with an antiretroviral drug nelfinavir.

  Biochemical and biophysical research communications 20101105

• Stress degradation studies of nelfinavir mesylate by Fourier transform infrared spectroscopy.

  Journal of pharmaceutical and biomedical analysis 20101102

• Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance.

  Sexually transmitted diseases 20101101

• HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.

  Journal of molecular and cellular cardiology 20101101

• Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats.

  Circulation 20101101

• Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.

  Investigational new drugs 20101001

• Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus.

  Antiviral research 20101001

• Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs.

  Journal of veterinary pharmacology and therapeutics 20101001

• Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.

  Journal of molecular graphics & modelling 20100901

• Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir.

  European journal of obstetrics, gynecology, and reproductive biology 20100901

• CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20100701

• New prospects for nelfinavir in non-HIV-related diseases.

  Current molecular pharmacology 20100601

• Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.

  Biopharmaceutics & drug disposition 20100301

• Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.

  PLoS neglected tropical diseases 20100301

• Synthesis of new thienyl ring containing HIV-1 protease inhibitors: promising preliminary pharmacological evaluation against recombinant HIV-1 proteases.

  Journal of medicinal chemistry 20100225

• Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100201

• Asymmetric synthesis of the potent HIV-protease inhibitor, nelfinavir.

  The Journal of organic chemistry 20100115

• Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.

  AIDS (London, England) 20100102

• Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.

  Journal of molecular graphics & modelling 20100101

• HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro.

  The American journal of tropical medicine and hygiene 20100101

• The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization.

  Molecular cancer 20100101

• Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells.

  Breast cancer research : BCR 20100101

• Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape.

  BMC bioinformatics 20100101

• Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice.

  BMC gastroenterology 20100101

• In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.

  Antiviral therapy 20100101

• Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir.

  European journal of obstetrics, gynecology, and reproductive biology 20091201

• Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20091201

• Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats.

  Biopharmaceutics & drug disposition 20091201

• Marked tumor response and fatal hemoptysis during radiation for lung cancer in a human immunodeficiency virus-positive patient taking nelfinavir.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091201

• Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.

  Biochemical and biophysical research communications 20091113

• EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.

  Toxicology letters 20091112

• General 4-week toxicity study with EMS in the rat.

  Toxicology letters 20091112

• Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.

  Toxicology letters 20091112

• In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human.

  Toxicology letters 20091112

• Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.

  Toxicology letters 20091112

• The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?

  Toxicology letters 20091112

• EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.

  Toxicology letters 20091112

• What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.

  Toxicology letters 20091112

• Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.

  Toxicology letters 20091112

• In vivo genotoxicity of EMS: statistical assessment of the dose response curves.

  Toxicology letters 20091112

• The Viracept-EMS case: impact and outlook.

  Toxicology letters 20091112

• Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.

  Journal of pharmaceutical sciences 20091101

• Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite.

  British journal of clinical pharmacology 20091101

• Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.

  Current HIV research 20091101

• Antiretroviral compounds and cholesterol efflux from macrophages.

  Atherosclerosis 20091001

• Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism.

  Experimental parasitology 20091001

• Signaling pathways in adenoid cystic cancers: implications for treatment.

  Cancer biology & therapy 20091001

• Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress.

  Cancer letters 20090908

• Fulminant hepatic failure associated with antiretroviral therapy in a pregnant woman.

  International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 20090901

• Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research.

  Current clinical pharmacology 20090901

• Effects of antiretroviral drug recall on perception of therapy benefits and on adherence to antiretroviral treatment in HIV-infected children.

  Current HIV research 20090901

• Pregnancy does not increase CYP3A or P-glycoprotein activity in the non-human primate, Macaca nemestrina.

  The Journal of pharmacology and experimental therapeutics 20090801

• A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.

  The Cochrane database of systematic reviews 20090708

• Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha.

  Journal of viral hepatitis 20090701

• The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT.

  International journal of radiation oncology, biology, physics 20090701

• CD4 responses in the setting or suboptimal virological responses to antiretroviral therapy: features, outcomes, and associated factors.

  AIDS research and human retroviruses 20090701

• Pharmacokinetic study and comparative bioavailability of two nelfinavir tablet formulations in Iranian healthy volunteers after a low-dose administration.

  International journal of clinical pharmacology and therapeutics 20090701

• Effectiveness of commercial inhibitors against subtype F HIV-1 protease.

  Journal of enzyme inhibition and medicinal chemistry 20090601

• Postreceptoral adipocyte insulin resistance induced by nelfinavir is caused by insensitivity of PKB/Akt to phosphatidylinositol-3,4,5-trisphosphate.

  Endocrinology 20090601

• As in humans, pregnancy increases the clearance of the protease inhibitor nelfinavir in the nonhuman primate Macaca nemestrina.

  The Journal of pharmacology and experimental therapeutics 20090601

• Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.

  Proteins 20090515

• Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.

  Journal of computer-aided molecular design 20090501

• Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.

  Drug and alcohol dependence 20090501

• Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis.

  American journal of physiology. Gastrointestinal and liver physiology 20090501

• Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection: the VIRAKINETICS II study.

  Current HIV research 20090501

• HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone.

  Experimental biology and medicine (Maywood, N.J.) 20090401

• The influence of the patients' educational levels on socioeconomic, clinical, immunological and virological endpoints.

  AIDS care 20090401

• A mass spectrometry based imaging method developed for the intracellular detection of HIV protease inhibitors.

  Rapid communications in mass spectrometry : RCM 20090401

• Therapeutic effects of Nigella sativa on chronic HAART-induced hyperinsulinemia in rats.

  Canadian journal of physiology and pharmacology 20090401

• Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.

  Drug metabolism and disposition: the biological fate of chemicals 20090301

• Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.

  The Journal of antimicrobial chemotherapy 20090301

• Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study.

  Journal of clinical pharmacology 20090301

• Depot-specific adipocyte cell lines reveal differential drug-induced responses of white adipocytes--relevance for partial lipodystrophy.

  American journal of physiology. Endocrinology and metabolism 20090201

• Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis.

  Cancer biology & therapy 20090201

• Pharmacokinetics of human immunodeficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats.

  Biological & pharmaceutical bulletin 20090201

• Nelfinavir: a magic bullet to annihilate cancer cells?

  Cancer biology & therapy 20090201

• Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.

  Clinical chemistry 20090101

• Anti-HIV drugs for cancer therapeutics: back to the future?

  The Lancet. Oncology 20090101

• Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.

  PloS one 20090101

• HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis.

  PloS one 20090101

• Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum.

  HIV clinical trials 20090101

• Clinicians' knowledge of 2007 Food and Drug Administration recommendation to discontinue nelfinavir use during pregnancy.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial.

  HIV clinical trials 20090101

• Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells.

  Biochemical and biophysical research communications 20081226

• A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.

  Drug metabolism and disposition: the biological fate of chemicals 20081201

• Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.

  HIV medicine 20081101

• Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors.

  The Journal of infectious diseases 20081101

• Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats.

  Biopharmaceutics & drug disposition 20081101

• Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.

  Therapeutic drug monitoring 20081001

• Bullous skin eruption in an HIV patient during antiretroviral drugs therapy.

  Dermatologic therapy 20081001

• Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir.

  Drug metabolism and disposition: the biological fate of chemicals 20080701

• Possible antiretroviral therapy-warfarin drug interaction.

  Pharmacotherapy 20080701

• HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice.

  The Journal of clinical investigation 20080602

• Uncomplicated outcome after an accidental overdose of nevirapine in a newborn.

  European journal of pediatrics 20080601

• Quality control of protease inhibitors.

  Journal of pharmaceutical sciences 20080601

• Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080601

• Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans.

  Cancer biology & therapy 20080501

• Drug-specific effect of nelfinavir and stavudine on primary culture of human preadipocytes.

  Journal of acquired immune deficiency syndromes (1999) 20080501

• Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

  The Pediatric infectious disease journal 20080501

• Progress towards the use of HIV protease inhibitors in cancer therapy.

  Cancer biology & therapy 20080501

• Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.

  British journal of clinical pharmacology 20080401

• Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.

  Clinical pharmacology and therapeutics 20080201

• Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.

  Contraception 20080201

• Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry.

  Pharmeuropa scientific notes 20080201

• The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease.

  Biochemistry 20080115

• Synthesis, anti-HIV and antitubercular activities of nelfinavir diester derivatives.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080101

• Nelfinavir monotherapy increases naïve T-cell numbers in HIV-negative healthy young adults.

  Frontiers in bioscience : a journal and virtual library 20080101

• Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy.

  Autophagy 20080101

• Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.

  Pharmacotherapy 20080101

• Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.

  Journal of neurovirology 20080101

• Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir.

  BMC neuroscience 20080101

• [Novel synthesis and spectral characterization of nelfinavir].

  Guang pu xue yu guang pu fen xi = Guang pu 20080101

• Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.

  HIV clinical trials 20080101

• Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy.

  Acta poloniae pharmaceutica 20080101

• Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.

  Antiviral therapy 20080101

• Changes are recommended in use of nelfinavir.

  HIV clinician 20080101

• Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.

  Antiviral therapy 20080101

• The levator aponeurosis exposed.

  Ophthalmic plastic and reconstructive surgery 20080101

• Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence.

  PloS one 20080101

• Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.

  Journal of molecular biology 20071207

• Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine.

  The Journal of infectious diseases 20071201

• Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.

  AIDS research and human retroviruses 20071201

• Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.

  AIDS (London, England) 20071130

• HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.

  Cancer research 20071115

• Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.

  European journal of clinical pharmacology 20071101

• Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.

  Journal of medical virology 20071101

• Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.

  British journal of clinical pharmacology 20071101

• Promoter polymorphisms and allelic imbalance in ABCB1 expression.

  Pharmacogenetics and genomics 20071101

• Pfizer warns health care professionals of possible carcinogen in Viracept.

  The AIDS reader 20071101

• European license for Viracept re-established by EC.

  AIDS patient care and STDs 20071101

• Caution regarding nelfinavir use in children and pregnant women.

  AIDS clinical care 20071101

• FDA notifications. FDA provides more info in response to Viracept recall.

  AIDS alert 20071101

• Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.

  Journal of molecular graphics & modelling 20071001

• Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence.

  Cell death and differentiation 20071001

• Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.

  Drug metabolism and disposition: the biological fate of chemicals 20071001

• Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification.

  The Journal of antimicrobial chemotherapy 20071001

• High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004.

  AIDS (London, England) 20071001

• Viracept recommended for reinstatement in Europe.

  AIDS patient care and STDs 20071001

• Biomedicine. HIV drug shows promise as potential cancer treatment.

  Science (New York, N.Y.) 20070907

• Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.

  Clinical pharmacology and therapeutics 20070901

• Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid.

  Drug metabolism and disposition: the biological fate of chemicals 20070901

• Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070901

• Recall of AIDS drug hits world's poorest patients.

  The AIDS reader 20070901

• Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.

  Journal of acquired immune deficiency syndromes (1999) 20070815

• Regulation of adipocyte lipolysis by degradation of the perilipin protein: nelfinavir enhances lysosome-mediated perilipin proteolysis.

  The Journal of biological chemistry 20070727

• Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070701

• Viracept contaminated in Europe.

  AIDS patient care and STDs 20070701

• Antiretroviral agents and acid-base balance at delivery of the neonate.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20070701

• Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20070701

• Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.

  Journal of drugs in dermatology : JDD 20070701

• Evaluation of Elisa test for therapeutic monitoring of Nelfinavir in HIV-positive patients.

  The new microbiologica 20070701

• Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion.

  The Journal of biological chemistry 20070608

• Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.

  Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20070601

• Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients.

  The Journal of infection 20070601

• Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir.

  Hematological oncology 20070601

• Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.

  Pharmacotherapy 20070601

• Factors associated with poor immunologic responses despite viral suppression in markedly immunosuppressed patients.

  AIDS patient care and STDs 20070601

• Effects of antiretroviral agents during pregnancy on liver enzymes and amylase in HIV-exposed, uninfected newborn infants.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20070601

• Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.

  Biochemical pharmacology 20070515

• HIV protease inhibitors enhance the efficacy of irradiation.

  Cancer research 20070515

• Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20070501

• Paronychia in an HIV-infected patient under nelfinavir therapy.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20070501

• HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo.

  Apoptosis : an international journal on programmed cell death 20070501

• Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.

  Journal of acquired immune deficiency syndromes (1999) 20070501

• Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.

  Cancer research 20070501

• Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.

  AIDS (London, England) 20070423

• Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.

  Journal of medicinal chemistry 20070419

• An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401

• HIV1 protease inhibitors selectively induce inflammatory chemokine expression in primary human osteoblasts.

  Antiviral research 20070401

• The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response.

  Neoplasia (New York, N.Y.) 20070401

• Instrumental variables and interactions in the causal analysis of a complex clinical trial.

  Statistics in medicine 20070330

• High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.

  Journal of pharmaceutical and biomedical analysis 20070312

• Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.

  The Journal of antimicrobial chemotherapy 20070301

• Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.

  Clinical pharmacology and therapeutics 20070201

• HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.

  Cancer research 20070201

• HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts.

  AIDS research and human retroviruses 20070201

• Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070101

• Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.

  AIDS research and human retroviruses 20070101

• A comparison of different protease inhibitors on coronary heart disease risk.

  Connecticut medicine 20070101

• A virological benefit from an induction/maintenance strategy: the Forte trial.

  Antiviral therapy 20070101

• Effect of transporter modulation on the emergence of nelfinavir resistance in vitro.

  Antiviral therapy 20070101

• Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.

  Clinical pharmacokinetics 20070101

• HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?

  Antiviral therapy 20070101

• Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).

  HIV clinical trials 20070101

• Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.

  Neurosurgical focus 20070101

• NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.

  British journal of cancer 20061218

• Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20061215

• N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.

  AIDS research and human retroviruses 20061201

• Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.

  AIDS (London, England) 20061128

• Evaluation of an International Pharmacopoeia method for the analysis of nelfinavir mesilate by liquid chromatography.

  Journal of chromatography. A 20061117

• Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors.

  Research in microbiology 20061101

• Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells.

  Diabetes, obesity & metabolism 20061101

• Pharmacokinetics of nelfinavir in subjects with hepatic impairment.

  Journal of clinical pharmacology 20061101

• CD4 count and viral load time-courses in patients treated with highly active antiretroviral therapy and association with the CDC staging system.

  HIV medicine 20061101

• HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells.

  Neoplasia (New York, N.Y.) 20061101

• Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.

  Clinical pharmacology and therapeutics 20061001

• Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy.

  Cancer research 20060915

• Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.

  British journal of clinical pharmacology 20060901

• Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.

  Anti-cancer drugs 20060901

• [Adherence, pharmacokinetic 'tolerance capacity' and HIV resistance development].

  Praxis 20060816

• Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases.

  The Journal of antimicrobial chemotherapy 20060801

• Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.

  British journal of clinical pharmacology 20060801

• The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.

  British journal of clinical pharmacology 20060801

• Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C.

  The Journal of antimicrobial chemotherapy 20060701

• Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.

  HIV medicine 20060701

• [Clinical and pharmacokinetic interactions between methadone and nelfinavir (Nemesia study)].

  Medicina clinica 20060610

• Determination of nelfinavir mesylate as bulk drug and in pharmaceutical dosage form by stability indicating HPLC.

  Journal of pharmaceutical and biomedical analysis 20060607

• Cooperative contribution of gag substitutions to nelfinavir-dependent enhancement of precursor cleavage and replication of human immunodeficiency virus type-1.

  Antiviral research 20060601

• Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance.

  Journal of substance abuse treatment 20060601

• Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.

  The Annals of pharmacotherapy 20060601

• Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.

  The Pediatric infectious disease journal 20060601

• Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors.

  Microbes and infection 20060601

• Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.

  The Journal of general virology 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy.

  AIDS (London, England) 20060424

• Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.

  AIDS (London, England) 20060424

• Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate.

  Virology 20060410

• Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy.

  The Journal of infection 20060401

• Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats.

  Drug metabolism and disposition: the biological fate of chemicals 20060401

• A review of nelfinavir for the treatment of HIV infection.

  Expert opinion on drug metabolism & toxicology 20060401

• Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.

  AIDS (London, England) 20060321

• Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: the role of CYP3A and P-glycoprotein.

  The Journal of pharmacology and experimental therapeutics 20060301

• Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users.

  Biopharmaceutics & drug disposition 20060301

• A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.

  HIV medicine 20060301

• Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.

  HIV medicine 20060301

• Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.

  Pediatrics 20060301

• HIV-1 protease inhibitors and cytomegalovirus vMIA induce mitochondrial fragmentation without triggering apoptosis.

  Cell death and differentiation 20060201

• HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir.

  Journal of leukocyte biology 20060201

• The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers.

  Journal of clinical pharmacology 20060201

• Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors.

  AIDS (London, England) 20060109

• Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women.

  Diabetes/metabolism research and reviews 20060101

• HIV protease inhibitors: suppression of insulin secretion by inhibition of voltage-dependent K+ currents and anion currents.

  The Journal of pharmacology and experimental therapeutics 20060101

• Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.

  Basic & clinical pharmacology & toxicology 20060101

• Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.

  BMC infectious diseases 20060101

• Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients.

  Scandinavian journal of infectious diseases 20060101

• Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.

  BMC infectious diseases 20060101

• Antiretroviral agents during pregnancy: consequences on hematologic parameters in HIV-exposed, uninfected newborn infant.

  European journal of obstetrics, gynecology, and reproductive biology 20060101

• Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG.

  Antiviral therapy 20060101

• Detection of HIV protease inhibitors in alveolar epithelial lining fluid: relevance for modulation of pneumocystis infection in the course of HAART.

  The Journal of eukaryotic microbiology 20060101

• Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents.

  Antiviral therapy 20060101

• Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

  The Journal of infectious diseases 20051201

• Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy.

  International journal of STD & AIDS 20051201

• Increase in thyroid follicular cell tumors in nelfinavir-treated rats observed in a 2-year carcinogenicity study is consistent with a rat-specific mechanism of thyroid neoplasia.

  Human & experimental toxicology 20051201

• Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.

  AIDS (London, England) 20051104

• Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051015

• The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.

  Journal of clinical pharmacology 20051001

• Limited sampling strategy for the estimation of systemic exposure to the protease inhibitor nelfinavir.

  Therapeutic drug monitoring 20051001

• Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.

  British journal of clinical pharmacology 20051001

• Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

  The Pediatric infectious disease journal 20051001

• Nelfinavir in HIV-HCV coinfected patients: a 24-month follow-up in a cohort of 82 patients.

  AIDS research and human retroviruses 20051001

• HIV antiretroviral agents inhibit protein synthesis and decrease ribosomal protein S6 and 4EBP1 phosphorylation in C2C12 myocytes.

  AIDS research and human retroviruses 20051001

• Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo.

  Pharmacogenetics and genomics 20050901

• Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.

  Journal of acquired immune deficiency syndromes (1999) 20050901

• The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.

  HIV medicine 20050901

• Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.

  Journal of medical virology 20050801

• TDM: therapeutic drug measuring or therapeutic drug monitoring?

  Therapeutic drug monitoring 20050801

• HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20050801

• Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.

  The Journal of clinical investigation 20050701

• HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling.

  Cancer science 20050701

• Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.

  The Journal of infectious diseases 20050615

• The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice.

  Journal of pharmaceutical sciences 20050601

• Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life.

  Journal of acquired immune deficiency syndromes (1999) 20050601

• Effect of antiretroviral drugs on maternal CD4 lymphocyte counts, HIV-1 RNA levels, and anthropometric parameters of their neonates.

  Clinics (Sao Paulo, Brazil) 20050601

• Abnormalities in plasma fatty acid composition in human immunodeficiency virus-infected children treated with protease inhibitors.

  Acta paediatrica (Oslo, Norway : 1992) 20050601

• Nelfinavir and nevirapine side effects during pregnancy.

  AIDS (London, England) 20050520

• The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.

  HIV medicine 20050501

• Hepatotoxicity and nelfinavir: a meta-analysis.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20050501

• Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.

  The Journal of antimicrobial chemotherapy 20050401

• Postexposure prophylaxis after sexual assaults: a prospective cohort study.

  Sexually transmitted diseases 20050401

• Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20050401

• Lopinavir/r versus nelfinavir as salvage therapy.

  The Pediatric infectious disease journal 20050401

• An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children.

  AIDS (London, England) 20050304

• Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.

  The American journal of cardiology 20050301

• Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects.

  International journal of clinical pharmacology and therapeutics 20050301

• Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations.

  HIV medicine 20050301

• C/EBPalpha reverses the anti-adipogenic effects of the HIV protease inhibitor nelfinavir.

  Biochemical and biophysical research communications 20050211

• Immunotoxicity evaluation of nelfinavir in rats.

  Human & experimental toxicology 20050201

• Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.

  The journal of physical chemistry. B 20050113

• Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101

• HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimens.

  Journal of clinical laboratory analysis 20050101

• Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20050101

• The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function.

  Antiviral therapy 20050101

• The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.

  Antiviral therapy 20050101

• Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir.

  Clinical pharmacokinetics 20050101

• In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs.

  Arzneimittel-Forschung 20050101

• The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells.

  Antiviral therapy 20050101

• Nelfinavir: a review of its use in the management of HIV infection.

  Drugs 20050101

• Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).

  HIV clinical trials 20050101

• Effectiveness of step-wise intervention plan for managing nelfinavir-associated diarrhea: a pilot study.

  HIV clinical trials 20050101

• High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

  Clinical pharmacokinetics 20050101

• Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.

  International journal of immunopathology and pharmacology 20050101

• In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.

  Antiviral therapy 20050101

• Safety of nelfinavir use during pregnancy. An experimental approach in rats.

  Clinical and experimental obstetrics & gynecology 20050101

• Nelfinavir induces necrosis of 3T3F44-2A adipocytes by oxidative stress.

  Journal of acquired immune deficiency syndromes (1999) 20041215

• Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.

  Drug metabolism and disposition: the biological fate of chemicals 20041201

• Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers.

  British journal of clinical pharmacology 20041201

• Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.

  The Journal of endocrinology 20041201

• The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.

  Clinical pharmacology and therapeutics 20041201

• Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy.

  Antiviral therapy 20041201

• Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

  AIDS (London, England) 20041119

• Alternative, age- and viral load-related routes of nelfinavir resistance in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.

  The Pediatric infectious disease journal 20041101

• [Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].

  Nederlands tijdschrift voor geneeskunde 20041009

• Therapeutic drug monitoring of nelfinavir in pregnancy: a case report.

  Therapeutic drug monitoring 20041001

• Subnanogram on-line column-switching liquid chromatographic-tandem mass spectrometric quantification method for nelfinavir and methoxyphenol metabolite M1 in rat plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040925

• Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.

  AIDS (London, England) 20040903

• Sweet's syndrome following abacavir therapy.

  Journal of the American Academy of Dermatology 20040901

• Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.

  The Journal of pediatrics 20040901

• Nelfinavir plasma concentrations are low during pregnancy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040901

• Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy.

  American journal of obstetrics and gynecology 20040901

• HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040815

• Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040801

• Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.

  American journal of obstetrics and gynecology 20040801

• Evaluation of endogenous pig retrovirus expression and of tumorigenicity in nude mice.

  Veterinary research communications 20040801

• Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

  Prescrire international 20040801

• SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.

  AIDS (London, England) 20040723

• Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.

  The Journal of infectious diseases 20040715

• HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

  The Journal of pharmacology and experimental therapeutics 20040701

• Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.

  Journal of acquired immune deficiency syndromes (1999) 20040701

• Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.

  HIV medicine 20040701

• [Impairment of IRS-2 signaling in rat insulinoma INS-1 cells by nelfinavir].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20040701

• HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus.

  Biochemical and biophysical research communications 20040604

• Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.

  Journal of acquired immune deficiency syndromes (1999) 20040601

• Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta.

  Diabetologia 20040601

• Risk of birth defects associated with nelfinavir exposure during pregnancy.

  Obstetrics and gynecology 20040601

• Direct interference of HIV protease inhibitors with pancreatic beta-cell function.

  Naunyn-Schmiedeberg's archives of pharmacology 20040601

• Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.

  Pharmacotherapy 20040601

• Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling.

  American journal of physiology. Cell physiology 20040501

• [HAART and pregnancy. Nelfinavir superiority in hepatotoxicity].

  MMW Fortschritte der Medizin 20040426

• Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

  The Journal of infectious diseases 20040401

• Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction.

  Clinical pharmacology and therapeutics 20040401

• Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.

  Journal of acquired immune deficiency syndromes (1999) 20040401

• Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.

  Antiviral therapy 20040401

• Lamivudine 300 mg in HIV infection: dose change. Once-a-day dosing.

  Prescrire international 20040401

• Comparison of regimens as initial therapy for HIV.

  The New England journal of medicine 20040304

• In vitro studies of the effects of HAART drugs and excipients on activity of digestive enzymes.

  Pharmaceutical research 20040301

• Protease inhibitor therapy improves protein catabolism in prepubertal children with HIV infection.

  Journal of pediatric endocrinology & metabolism : JPEM 20040301

• Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.

  Antiviral research 20040301

• Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.

  Organic & biomolecular chemistry 20040207

• Mitochondrial effects of antiretroviral therapies in asymptomatic patients.

  Antiviral therapy 20040201

• Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.

  Antiviral therapy 20040201

• Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients.

  Antiviral therapy 20040201

• Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.

  AIDS (London, England) 20040123

• Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

  The Journal of infectious diseases 20040101

• The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20040101

• Antiretroviral therapy influences cellular susceptibility to apoptosis in vivo.

  Frontiers in bioscience : a journal and virtual library 20040101

• A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102).

  HIV clinical trials 20040101

• Peptidomimetic inhibitors of HIV protease.

  Current topics in medicinal chemistry 20040101

• Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir.

  The American journal on addictions 20040101

• Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy).

  HIV clinical trials 20040101

• HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants.

  Cardiovascular toxicology 20040101

• Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.

  HIV clinical trials 20040101

• [Development of microchips for the detection of mutations of HIV-1 variability to protease inhibitors and the usage results].

  Voprosy virusologii 20040101

• Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20040101

• Anti-HIV agents. Nelfinavir levels during pregnancy.

  TreatmentUpdate 20040101

• Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.

  Biochemistry 20031230

• Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20031215

• Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

  The New England journal of medicine 20031211

• Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

  The New England journal of medicine 20031211

• [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].

  MMW Fortschritte der Medizin 20031211

• Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

  AIDS (London, England) 20031205

• Absence of embryo-fetal toxicity in rats or rabbits following oral dosing with nelfinavir.

  Regulatory toxicology and pharmacology : RTP 20031201

• Absence of reproductive and developmental toxicity in rats following oral dosing with nelfinavir.

  Regulatory toxicology and pharmacology : RTP 20031201

• Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults.

  Therapeutic drug monitoring 20031201

• [Immunological, virological and clinical response in patients infected with HIV after highly active antiviral therapy with nelfinavir: prospective cohort study].

  Enfermedades infecciosas y microbiologia clinica 20031201

• A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.

  Antiviral therapy 20031201

• A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20031201

• Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.

  Dermatology online journal 20031201

• HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk.

  The Journal of biological chemistry 20031128

• Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation.

  AIDS (London, England) 20031121

• A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.

  The Journal of clinical endocrinology and metabolism 20031101

• Nelfinavir safe and effective in HIV/HCV patients.

  AIDS patient care and STDs 20031101

• Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.

  AIDS (London, England) 20031017

• Modulation of the LDL receptor and LRP levels by HIV protease inhibitors.

  Journal of lipid research 20031001

• Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir, and nelfinavir in children and adults.

  Therapeutic drug monitoring 20031001

• Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.

  AIDS (London, England) 20030926

• A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

  The Journal of infectious diseases 20030901

• Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.

  Pediatrics 20030901

• [Use of antiretroviral drugs in HIV infected children in a tropical area: a real benefit].

  Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 20030901

• Pfizer announces free drug program.

  AIDS patient care and STDs 20030901

• Characterizing classes of antiretroviral drugs by genotype.

  Statistics in medicine 20030830

• Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.

  Annals of internal medicine 20030819

• Summaries for patients. Does marijuana affect viral loads in people with HIV?

  Annals of internal medicine 20030819

• The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20030801

• HIV protease inhibitors acutely impair glucose-stimulated insulin release.

  Diabetes 20030701

• FDA notifications. New dosing option approved for Viracept.

  AIDS alert 20030701

• pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.

  AIDS research and human retroviruses 20030701

• Less dose burden for Viracept.

  AIDS patient care and STDs 20030701

• Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.

  AIDS (London, England) 20030701

• Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.

  Therapeutic drug monitoring 20030601

• Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.

  Therapeutic drug monitoring 20030601

• Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030601

• Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.

  Antiviral therapy 20030601

• Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.

  AIDS (London, England) 20030523

• Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women.

  AIDS (London, England) 20030523

• Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.

  Clinical pharmacology and therapeutics 20030501

• Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.

  AIDS patient care and STDs 20030501

• [Highly effective drug without modifying the lipid profile. Atazanavir, the protease inhibitor for 'once daily' administration].

  MMW Fortschritte der Medizin 20030428

• [No selection of mutations. 908 raises genetic resistance barrier].

  MMW Fortschritte der Medizin 20030428

• [A light meal at the same time is enough. Advantages of natural enhancement of nelfinavir].

  MMW Fortschritte der Medizin 20030428

• Sildenafil does not alter nelfinavir pharmacokinetics.

  Therapeutic drug monitoring 20030401

• Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.

  The Annals of pharmacotherapy 20030401

• Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.

  The Journal of infectious diseases 20030401

• NEAT results released.

  AIDS patient care and STDs 20030401

• Resistance data also presented.

  AIDS patient care and STDs 20030401

• Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.

  Antiviral therapy 20030401

• Prevalence and virologic consequences of HIV-1 genotype mutations detected in a cohort of 161 Italian patients receiving a nelfinavir-based highly active antiretroviral therapy.

  Journal of chemotherapy (Florence, Italy) 20030401

• HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D.

  AIDS (London, England) 20030307

• Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series.

  AIDS (London, England) 20030307

• Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion.

  AIDS research and human retroviruses 20030301

• Prospective comparison of first-line nelfinavir therapy versus nelfinavir introduction in rescue antiretroviral regimens.

  AIDS patient care and STDs 20030301

• Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.

  The Journal of infectious diseases 20030215

• Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations.

  AIDS (London, England) 20030214

• Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.

  Therapeutic drug monitoring 20030201

• Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.

  Biological & pharmaceutical bulletin 20030201

• Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers.

  British journal of clinical pharmacology 20030201

• SOLO trial results released.

  AIDS patient care and STDs 20030201

• Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.

  International journal of STD & AIDS 20030201

• Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.

  Antiviral therapy 20030201

• A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.

  Biochemistry 20030128

• Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors.

  European journal of medical research 20030128

• A process in need is a process indeed: scalable enantioselective synthesis of chiral compounds for the pharmaceutical industry.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20030120

• Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors.

  AIDS (London, England) 20030103

• Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

  Journal of acquired immune deficiency syndromes (1999) 20030101

• Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.

  HIV medicine 20030101

• The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients.

  HIV medicine 20030101

• Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.

  The Pediatric infectious disease journal 20030101

• Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.

  The Pediatric infectious disease journal 20030101

• Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors.

  The Pediatric infectious disease journal 20030101

• Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy.

  Clinical pharmacology and therapeutics 20030101

• Bone appetite--using food to boost your Viracept.

  Positively aware : the monthly journal of the Test Positive Aware Network 20030101

• L-glutamine supplementation improves nelfinavir-associated diarrhea in HIV-infected individuals.

  HIV clinical trials 20030101

• Differences in durability of treatment with initial PI-based regimens.

  HIV clinical trials 20030101

• Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. New formulation of nelfinavir on the way.

  TreatmentUpdate 20030101

• Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Does Roche's nelfinavir cause less diarrhea?

  TreatmentUpdate 20030101

• Diurnal variation of plasma protease inhibitor concentrations.

  AIDS (London, England) 20021206

• Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration.

  Drug metabolism and disposition: the biological fate of chemicals 20021201

• Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir.

  Journal of acquired immune deficiency syndromes (1999) 20021201

• Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).

  Antiviral therapy 20021201

• Chronic cough induced by abacavir apart from a context of hypersensitivity.

  Allergie et immunologie 20021201

• Estimating the length of the first antiretroviral therapy regiment durability in São Paulo, Brazil.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20021201

• NEAT trial releases results.

  AIDS patient care and STDs 20021201

• Nelfinavir tolerated in HCV patients.

  AIDS patient care and STDs 20021201

• Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20021115

• Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20021115

• Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.

  Diabetes 20021101

• Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers.

  Pharmaceutical research 20021101

• Supplement fix for nelfinavir-related diarrhea.

  TreatmentUpdate 20021101

• Limited effect of food composition on the pharmacokinetics of nelfinavir administered twice daily.

  European journal of medical research 20021029

• Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.

  Journal of pharmaceutical and biomedical analysis 20021015

• Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation.

  Journal of virological methods 20021001

• Symptomatic orthostasis with extended-release nifedipine and protease inhibitors.

  Pharmacotherapy 20021001

• [Antiretroviral therapy with nelfinavir for patient infected, by HIV and secondary diabetes mellitus due to indinavir].

  Medicina clinica 20020928

• Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.

  The Journal of infectious diseases 20020901

• Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20020901

• Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.

  Clinical and diagnostic laboratory immunology 20020901

• Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.

  Medical science monitor : international medical journal of experimental and clinical research 20020901

• Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity.

  Antiviral therapy 20020901

• [HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20020901

• The pharmacokinetics of nelfinavir in HIV-1-infected children.

  Therapeutic drug monitoring 20020801

• Low-dose ritonavir moderately enhances nelfinavir exposure.

  Clinical pharmacology and therapeutics 20020801

• Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.

  Clinical pharmacology and therapeutics 20020801

• Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.

  The Pediatric infectious disease journal 20020801

• Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.

  European journal of medical research 20020724

• Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

  JAMA 20020710

• Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.

  Biochemistry 20020709

• Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

  AIDS (London, England) 20020705

• Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.

  Proteins 20020701

• Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance.

  Journal of acquired immune deficiency syndromes (1999) 20020701

• Efavirenz liquid formulation in human immunodeficiency virus-infected children.

  The Pediatric infectious disease journal 20020701

• Pharmacokinetics of saquinavir in children during long term treatment.

  The Pediatric infectious disease journal 20020701

• Increasing choices for HIV therapy.

  The New England journal of medicine 20020627

• Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

  The New England journal of medicine 20020627

• Adhesive capsulitis of the shoulder in an HIV patient treated with nelfinavir.

  AIDS (London, England) 20020614

• High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.

  Therapeutic drug monitoring 20020601

• HIV genotype mutations evoked by nelfinavir-based regimens: frequency, background, and consequences on subsequent treatment options.

  Journal of acquired immune deficiency syndromes (1999) 20020601

• A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.

  Antiviral therapy 20020601

• A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).

  Antiviral therapy 20020601

• The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.

  The Southeast Asian journal of tropical medicine and public health 20020601

• Select HIV protease inhibitors alter bone and fat metabolism ex vivo.

  The Journal of biological chemistry 20020531

• Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.

  AIDS research and human retroviruses 20020520

• Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.

  The Journal of infectious diseases 20020515

• Needlestick transmission of hepatitis C.

  JAMA 20020508

• Prescribing practices in a population-based HIV postexposure prophylaxis program.

  AIDS (London, England) 20020503

• Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats.

  Drug metabolism and disposition: the biological fate of chemicals 20020501

• Male sexual dysfunction associated with antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20020501

• Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.

  Journal of acquired immune deficiency syndromes (1999) 20020415

• Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.

  Journal of acquired immune deficiency syndromes (1999) 20020415

• Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020401

• Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020401

• Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography.

  Therapeutic drug monitoring 20020401

• Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.

  Pediatrics 20020401

• Long-term response in patients receiving HAART including nelfinavir: experience from two Italian centers.

  Journal of chemotherapy (Florence, Italy) 20020401

• The utility of inhibitory quotients in determining the relative potency of protease inhibitors.

  AIDS (London, England) 20020329

• Severe HIV-associated thrombocytopenia despite effective highly active antiretroviral therapy in a vertically infected child.

  AIDS (London, England) 20020329

• The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.

  AIDS (London, England) 20020308

• Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.

  Lancet (London, England) 20020302

• Nelfinavir urinary stones.

  The Journal of urology 20020301

• Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20020301

• Metabolic response to a C-glucose load in human immunodeficiency virus patients before and after antiprotease therapy.

  Metabolism: clinical and experimental 20020301

• Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.

  Clinical pharmacology and therapeutics 20020301

• Delayed recovery of effector memory CD4+ T cells by highly active antiretroviral therapy in a patient with HIV-1 infection.

  The Tohoku journal of experimental medicine 20020301

• In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.

  The Journal of pharmacy and pharmacology 20020201

• Efficacy of highly active antiretroviral therapy in HIV-1 infected children.

  The Lancet. Infectious diseases 20020201

• Effect of antiretroviral combination therapies including efavirenz in heavily pretreated HIV-infected children.

  European journal of medical research 20020129

• Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.

  AIDS (London, England) 20020125

• Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.

  Lancet (London, England) 20020105

• Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.

  AIDS (London, England) 20020104

• Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

  AIDS (London, England) 20020104

• Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

  HIV clinical trials 20020101

• CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.

  Xenobiotica; the fate of foreign compounds in biological systems 20020101

• Atazanavir demonstrates antiviral efficacy and a favorable lipid profile at 48 weeks.

  The Journal of the Association of Nurses in AIDS Care : JANAC 20020101

• Cutaneous drug reaction case reports: from the world literature.

  American journal of clinical dermatology 20020101

• Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.

  Antiviral chemistry & chemotherapy 20020101

• Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.

  HIV clinical trials 20020101

• [Prophylactic antiretroviral therapy after sexual exposure to HIV: 93 cases].

  Annales de dermatologie et de venereologie 20020101

• A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.

  West African journal of medicine 20020101

• Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.

  HIV clinical trials 20020101

• Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.

  HIV clinical trials 20020101

• Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy.

  Swiss medical weekly 20011201

• Drugs for HIV infection.

  The Medical letter on drugs and therapeutics 20011126

• Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir.

  Carbohydrate research 20011121

• Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels.

  AIDS (London, England) 20011109

• Cheap AIDS drugs for developing countries.

  Trends in cell biology 20011101

• Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).

  AIDS (London, England) 20011019

• Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile.

  Journal of chemotherapy (Florence, Italy) 20011001

• Roche gives in to Brazil over AIDS drug.

  The Lancet. Infectious diseases 20011001

• An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy.

  Neurology 20010925

• Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.

  AIDS research and human retroviruses 20010920

• Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

  Archives of internal medicine 20010910

• Long-term response for nelfinavir.

  AIDS patient care and STDs 20010901

• Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.

  Antiviral therapy 20010901

• Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.

  Blood 20010815

• Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

  The New England journal of medicine 20010809

• Antiretroviral therapy for previously treated patients.

  The New England journal of medicine 20010809

• HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.

  Journal of acquired immune deficiency syndromes (1999) 20010801

• Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.

  Therapeutic drug monitoring 20010801

• Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.

  Therapeutic drug monitoring 20010801

• Lipid abnormalities in a healthcare worker receiving HIV prophylaxis.

  International journal of STD & AIDS 20010801

• Antiretroviral rounds. When success is a pain.

  AIDS clinical care 20010801

• Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.

  The Pediatric infectious disease journal 20010801

• P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

  AIDS (London, England) 20010727

• High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction.

  Journal of chromatography. B, Biomedical sciences and applications 20010715

• Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir.

  AIDS (London, England) 20010706

• CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.

  The British journal of ophthalmology 20010701

• Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.

  The Pediatric infectious disease journal 20010701

• Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).

  The Journal of infectious diseases 20010615

• Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.

  Journal of chromatography. B, Biomedical sciences and applications 20010615

• Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010601

• Design and synthesis of a conformationally restricted trans peptide isostere based on the bioactive conformations of saquinavir and nelfinavir.

  The Journal of organic chemistry 20010601

• The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes.

  Diabetes 20010601

• Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease.

  International journal of antimicrobial agents 20010601

• The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.

  Journal of acquired immune deficiency syndromes (1999) 20010601

• The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.

  Journal of the American Dietetic Association 20010601

• AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.

  Antiviral therapy 20010601

• Nelfinavir in expanded postexposure prophylaxis causing acute hepatitis with cholestatic features: two case reports.

  Infection control and hospital epidemiology 20010601

• Protease inhibitors and blood sugar problems.

  TreatmentUpdate 20010601

• Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.

  AIDS (London, England) 20010525

• Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment.

  AIDS (London, England) 20010525

• Editorial comment on Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.

  AIDS (London, England) 20010525

• Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.

  AIDS (London, England) 20010525

• Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010515

• Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Biomedical sciences and applications 20010505

• Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20010501

• Nelfinavir desensitization.

  The Annals of pharmacotherapy 20010501

• Ergotism related to interaction between nelfinavir and ergotamine.

  The American journal of medicine 20010501

• Lack of association between pregnancy and selected gastrointestinal adverse events among women prescribed nelfinavir.

  Journal of acquired immune deficiency syndromes (1999) 20010415

• Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.

  Analytical biochemistry 20010415

• Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.

  AIDS (London, England) 20010413

• Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.

  Antimicrobial agents and chemotherapy 20010401

• Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010401

• An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.

  Controlled clinical trials 20010401

• Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.

  Journal of acquired immune deficiency syndromes (1999) 20010401

• Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.

  AIDS (London, England) 20010330

• Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.

  The Journal of infectious diseases 20010301

• Lack of removal of nelfinavir during a haemodialysis session in an HIV-1 infected patient with hepatic and renal insufficiency.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010301

• The safety and antiviral effect of protease inhibitors in children.

  Pharmacotherapy 20010301

• Phase III trials for new PI.

  AIDS patient care and STDs 20010301

• Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir.

  Antiviral therapy 20010301

• An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy.

  AIDS (London, England) 20010216

• Failure of postexposure prophylaxis after sexual exposure to HIV.

  AIDS (London, England) 20010216

• Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.

  AIDS research and human retroviruses 20010210

• Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.

  Drug metabolism and disposition: the biological fate of chemicals 20010201

• Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20010201

• Pharmacology and clinical experience with saquinavir.

  Expert opinion on pharmacotherapy 20010201

• [Resistance to protease inhibitors].

  Enfermedades infecciosas y microbiologia clinica 20010201

• The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.

  AIDS (London, England) 20010126

• Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.

  AIDS research and human retroviruses 20010120

• The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.

  AIDS (London, England) 20010105

• Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.

  Journal of clinical laboratory analysis 20010101

• Kaletra versus nelfinavir.

  TreatmentUpdate 20010101

• Nelfinavir plus nevirapine plus two NRTIS as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatment.

  HIV clinical trials 20010101

• A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.

  HIV clinical trials 20010101

• Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure.

  HIV clinical trials 20010101

• Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.

  Clinical laboratory 20010101

• Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.

  HIV clinical trials 20010101

• Disseminated manifestation of Kaposi's Sarcoma in newly diagnosed AIDS in an african female.

  Medical science monitor : international medical journal of experimental and clinical research 20010101

• Viracept combination therapy as initial HAART demonstrates long-term response.

  The Journal of the Association of Nurses in AIDS Care : JANAC 20010101

• Caution with nelfinavir and some lipid-lowering drugs.

  TreatmentUpdate 20010101

• [Drug combination therapy for children infected with HIV/AIDS--own experience].

  Przeglad epidemiologiczny 20010101

• Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.

  Biological & pharmaceutical bulletin 20001201

• Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro.

  Antimicrobial agents and chemotherapy 20000901

• In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs.

  Antiviral therapy 20000901

• Small molecule inhibitor of HIV-1 nuclear import suppresses HIV-1 replication in human lymphoid tissue ex vivo: a potential addition to current anti-HIV drug repertoire.

  Antiviral research 20000801

• In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.

  The Journal of infectious diseases 20000501

• A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients.

  AIDS (London, England) 20000128

• Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases.

  The American journal of medicine 19991201

• Viracept and irregular heartbeat warning.

  The Body positive 19991001

• Symptomatic junctional bradycardia after treatment with nelfinavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 19990801

• A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin.

  Internal medicine (Tokyo, Japan) 19990301

• Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

  Antimicrobial agents and chemotherapy 19981001

• Nelfinavir associated with peripheral neuropathy in an HIV-infected patient.

  Infection 19980101

• Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

  Journal of medicinal chemistry 19971121

• Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.

  Antimicrobial agents and chemotherapy 19971001